A silent gap: underrepresentation of Latin American patients in pivotal genitourinary and skin cancer trials.

Background Latin America bears a growing burden of genitourinary (GU) and cutaneous malignancies but remains underrepresented in clinical trials that shape global standards of care. This underrepresentation raises ethical concerns and limits the generalizability of trial findings. We evaluated Latin...

Descripción completa

Detalles Bibliográficos
Publicado en:Oncologist Vol. 31; no. 8; pp. 1 - 4
Autores principales: Martinez-Castaneda, Erika Adriana, Overgaard, Ava Isabella De Pellegrin, Maselli-Schoueri, Jean Henri, Bell, Jennifer A H, Sridhar, Srikala S
Formato: research tables/charts Journal Article
Publicado: Oxford University Press / USA Aug2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=196038369&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 196038369
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10837159
        IJ7
      jtl: Oncologist
      issn: 10837159
      maglogo: N
    pubinfo:
      dt: Aug2026
      vid: 31
      iid: 8
      pid: 622
      pub: Oxford University Press / USA
    artinfo:
      ui:
        196038369
        196038369
        196038369
        10.1093/oncolo/oyag259
        196038369
      ppf: 1
      ppct: 3
      formats:
      tig:
        atl: A silent gap: underrepresentation of Latin American patients in pivotal genitourinary and skin cancer trials.
      aug:
        au:
          Martinez-Castaneda, Erika Adriana
          Overgaard, Ava Isabella De Pellegrin
          Maselli-Schoueri, Jean Henri
          Bell, Jennifer A H
          Sridhar, Srikala S
        affil: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2C4, Canada
      sug:
        subj:
          Cancer Patients Psychosocial Factors
          Urogenital Neoplasms
          Skin Neoplasms
          Patient Participation Evaluation
          Research Subject Recruitment Evaluation
          Clinical Trials
          Human
          Latin America
          Research Ethics
          Melanoma
          Ethnic Groups
          Descriptive Statistics
          Brazil
          Argentina
          Chile
          Mexico
          Colombia
          Comparative Studies
          Serial Publications
          Health Status Disparities
          Minority Groups
          Medical Practice
          Geographic Factors
          Research Subjects
      ab: Background Latin America bears a growing burden of genitourinary (GU) and cutaneous malignancies but remains underrepresented in clinical trials that shape global standards of care. This underrepresentation raises ethical concerns and limits the generalizability of trial findings. We evaluated Latin American (LATAM) representation in pivotal GU and skin cancer trials and explored barriers to equitable inclusion. Methods We reviewed pivotal phase II and III trials in advanced GU and cutaneous malignancies (melanoma and non-melanoma skin cancers) published between 2015 and 2024. Extracted data included trial site distribution, geographic representation, and ethnicity reporting. Results A total of 46 pivotal trials (29 GU and 17 skin cancer trials), representing 38 900 patients, were included. LATAM trial sites were present in 44 studies; however, only 25 trials reported enrollment of Hispanic/Latino patients, totaling 1303 patients (3.35%). Representation across LATAM was highly concentrated in a small number of countries, including Brazil (16 trials), Argentina (14), Chile (13), Mexico (12), and Colombia (6). Participation was greater in GU trials compared with skin cancer trials. Reporting transparency was limited: Hispanic/Latino representation was reported in only 2 main publications, 5 supplementary appendices, and 23 ClinicalTrials.gov records. Conclusions Only 6.3% of participants in pivotal GU and skin cancer trials were from Latin America. Limited infrastructure, regulatory barriers, and restricted research investment likely contribute to this disparity. Improving equitable representation will require intentional trial design, stronger regional investment, and policies that move beyond nominal participation toward meaningful inclusion.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N